Who are Ceftolozane / Tazobactam Injection's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftolozane-tazobactam-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ceftolozane / Tazobactam Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ceftolozane / Tazobactam Injection (Ceftolozane / Tazobactam Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam / beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Beta-lactam / beta-lactamase inhibitor combination Bacterial penicillin-binding proteins; beta-lactamase enzymes Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ceftolozane / Tazobactam Injection (Ceftolozane / Tazobactam Injection) — Weill Medical College of Cornell University. Ceftolozane inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, together providing broad-spectrum coverage against resistant gram-negative bacteria.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ceftolozane / Tazobactam Injection TARGET	Ceftolozane / Tazobactam Injection	Weill Medical College of Cornell University	marketed	Beta-lactam / beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins; beta-lactamase enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam / beta-lactamase inhibitor combination class)

Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceftolozane / Tazobactam Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftolozane-tazobactam-injection. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab